Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ADU-1604, an Anti-CTLA-4 Antibody, in Adults With Metastatic Melanoma

NCT03674502 is registered in ClinicalTrials.gov with Aduro Biotech, Inc. as lead sponsor.

NCT NCT03674502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03674502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ADU-1604, an Anti-CTLA-4 Antibody, in Adults With Metastatic Melanoma
Lead sponsor
Aduro Biotech, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
November 8, 2018
Completion date
August 9, 2019
Enrollment
4 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma